Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor.
about
Cation-independent mannose 6-phosphate receptor: a composite of distinct phosphomannosyl binding sitesTargeted approaches to induce immune tolerance for Pompe disease therapyDetection of Active Mammalian GH31 α-Glucosidases in Health and Disease Using In-Class, Broad-Spectrum Activity-Based Probes.Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe diseaseThe pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe diseaseN-glycans of recombinant human acid alpha-glucosidase expressed in the milk of transgenic rabbits.Pompe disease: from pathophysiology to therapy and back againAutophagy in skeletal muscle: implications for Pompe diseaseMolecular genetics of late onset glycogen storage disease II in Italy.Activity-based probes for functional interrogation of retaining β-glucuronidases.Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes.Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.Quantitative Proteomics of Human Fibroblasts with I1061T Mutation in Niemann-Pick C1 (NPC1) Protein Provides Insights into the Disease Pathogenesis.Proteolytic processing of the neuronal ceroid lipofuscinosis related lysosomal protein CLN5.Clinical Laboratory Experience of Blood CRIM Testing in Infantile Pompe DiseaseGlycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.A multi-tiered analytical approach for the analysis and quantitation of high-molecular-weight aggregates in a recombinant therapeutic glycoprotein.Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.Therapeutic approaches in glycogen storage disease type II/Pompe Disease.Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.The genotype-phenotype correlation in Pompe disease.α-Glucosidases and α-1,4-glucan lyases: structures, functions, and physiological actions.Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblastsBiotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases.Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.A Portrait of the Human Organelle Proteome In Space and Time during Cytomegalovirus InfectionProgress in Enzyme Replacement Therapy in Glycogen Storage Disease Type IIEnzyme enhancers for the treatment of Fabry and Pompe disease.Structure of human lysosomal acid α-glucosidase-a guide for the treatment of Pompe disease.Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts.Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease.Biochemical and structural study on a S529V mutant acid α-glucosidase responsive to pharmacological chaperones.
P2860
Q24646922-61395C3D-6E36-4144-BE4F-DA977EEC05B3Q26767363-3D62715D-11BE-4BA2-A847-09BB60CBAF03Q27300714-F41C2AF8-65F7-4F66-9948-91252DC49EFDQ28486167-F0258A1F-ABF2-4E19-8B9E-65F764C3BDF7Q28540925-86754842-A643-47C3-8159-18AF151335C9Q33273194-845EA030-7824-46F5-B8C9-39FF749186B3Q34054935-2F8E1F07-04BA-4E96-9778-6A8990D52F9DQ34170362-3D3B9223-58FE-4999-BB74-D3BCC8F51038Q34171682-16B40275-E990-48D0-9881-439DD1800716Q34557558-3CAB7AD4-EF56-42A2-B616-81B7A5FFDA42Q35007910-6206D1B7-4F91-42AA-B678-B22D3FC3DD50Q35049000-6AD9AA80-5800-4D07-9959-CB57B304BC9CQ35752654-4CDEC24C-0A2A-46A9-A680-80A6970C5D17Q36103923-8F48323A-60B2-49AC-97ED-2426F0D97578Q36109195-E11EC933-03B1-46B4-8E6E-161F5B85A86AQ36361194-D01E1DF4-6000-46FF-A855-9DE09FCB023AQ36543643-73A4476B-6ED0-4890-A8A7-F138D512C298Q37214538-4E8D4BBD-5019-4075-A380-8B5F5BA68061Q37219555-B63D247F-3F8E-44C0-B0DD-35C4C55FFA46Q37329535-900AABC1-D7E6-41A1-8410-A2A9C0851032Q37414571-6B10ED52-A476-4B7D-AD31-642BDA4836E4Q37976665-8998467E-21C5-4B9A-B911-2F531B201142Q38823312-D65FDA63-7EB3-4774-8C0D-CF4E489C45FDQ38982768-3F11D5F4-4433-4481-B1EE-54BC7A29E008Q39508157-A974F649-5761-4696-9DF4-ACD09C11451DQ39574331-CD20A5AF-23B2-4765-BA7B-C9298A9D3C25Q39616879-247F9E49-84B9-424D-943B-7DF9298BCF02Q40483606-7F21B485-4E2B-42DB-821E-E8019B1DD793Q41176219-AE1F4ADE-8226-43A6-BE87-0BEF1902EF57Q42018342-B8A4BB5A-6E78-4B09-B749-0A1288466F20Q42645986-2E6DE7E5-B88E-4B6C-B400-689C6573DB08Q43188193-E015604D-7710-481D-890C-6AA9BCF0D906Q47301525-273FFD22-5A29-4118-926A-B3AC601BDAF5Q51737715-382E0A4F-FC4A-4FAF-992C-88AC4B0E9A85Q51768630-AE5F23A7-D544-4E98-9B96-ED2973C73B0D
P2860
Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Lysosomal acid alpha-glucosida ...... from a single chain precursor.
@en
Lysosomal acid alpha-glucosida ...... from a single chain precursor.
@nl
type
label
Lysosomal acid alpha-glucosida ...... from a single chain precursor.
@en
Lysosomal acid alpha-glucosida ...... from a single chain precursor.
@nl
prefLabel
Lysosomal acid alpha-glucosida ...... from a single chain precursor.
@en
Lysosomal acid alpha-glucosida ...... from a single chain precursor.
@nl
P2093
P2860
P356
P1476
Lysosomal acid alpha-glucosida ...... from a single chain precursor.
@en
P2093
Karen L Albee
Karen L Lee
Kevin Brewer
Robert D Cauthron
Rodney J Moreland
Roger W Decker
Tim Edmunds
William M Canfield
X Kate Zhang
Xiaoying Jin
P2860
P304
P356
10.1074/JBC.M404008200
P407
P577
2004-11-01T00:00:00Z